Sold as Nuvaring. Every FDA application for this active ingredient: 1 branded and 5 generic.
As of Nov 15, 2026, FDA lists 6 applications for Ethinyl Estradiol; Etonogestrel (sold as Nuvaring), first approved Oct 3, 2001, with 3 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Assessing the Impact of Contraceptives on Bone Health Using 41CaOther Disorders of Bone Development and Growth · Penn State University | Phase 4 | Active, not recruiting | Feb 20, 2015 |
| Oct 3, 2001 | NuvaringNDA 21187 · New molecular entity | Organon USA Organon | 26 | Marketed |
| Dec 11, 2019 | EluryngANDA 210830 | Amneal | 2 | Marketed |
| Jan 13, 2021 | Ethinyl Estradiol; EtonogestrelANDA 204305 | Teva Pharms USA Inc | 1 | Marketed |
| Dec 9, 2021 | VeraringANDA 207577 | Dr Reddys Labs SA | 1 | Discontinued |
| Aug 5, 2022 | HaloetteANDA 211328 | Dr Reddys Labs SA | 1 | Marketed |
| Jun 29, 2023 | EnilloringANDA 211157 | Xiromed | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
